Insulet (NASDAQ:PODD) Price Target Raised to $158.00 at Raymond James
Insulet (NASDAQ:PODD) had its price objective increased by equities researchers at Raymond James from $135.00 to $158.00 in a research report issued on Wednesday, AnalystRatings.com reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James’ price objective points to a potential downside of 6.76% from the company’s previous close.
Other analysts have also recently issued reports about the stock. BMO Capital Markets boosted their price objective on shares of Insulet from $130.00 to $150.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 price objective (up from $160.00) on shares of Insulet in a research note on Wednesday. BidaskClub cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen set a $165.00 price objective on shares of Insulet and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Leerink Swann restated an “outperform” rating and issued a $185.00 price objective (up from $160.00) on shares of Insulet in a research note on Tuesday, September 24th. Ten research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $151.71.
Shares of Insulet stock opened at $169.46 on Wednesday. The firm has a fifty day simple moving average of $154.75 and a 200-day simple moving average of $130.77. The company has a current ratio of 4.72, a quick ratio of 3.91 and a debt-to-equity ratio of 2.43. Insulet has a 1-year low of $70.80 and a 1-year high of $171.96. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 3,389.20 and a beta of 0.96.
In other Insulet news, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the sale, the senior vice president now owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Shacey Petrovic sold 649 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,491 shares of company stock valued at $806,124. Corporate insiders own 3.50% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Advisors Preferred LLC bought a new stake in Insulet in the 2nd quarter valued at $38,000. Harvest Fund Management Co. Ltd bought a new stake in Insulet in the 2nd quarter valued at $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Insulet in the 2nd quarter valued at $97,000. Steward Partners Investment Advisory LLC bought a new stake in Insulet in the 2nd quarter valued at $119,000. Finally, Cerebellum GP LLC bought a new stake in Insulet in the 3rd quarter valued at $122,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Read More: What are the benefits of investing in REITs?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.